Daniel Yerace
Founder chez VININGS HOLDINGS INC.
Fortune : 300 150 $ au 31/03/2024
Profil
Daniel Yerace is the founder of Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. He is currently the Director & Vice President-Operations at Coeptis Therapeutics Holdings, Inc. Previously, he worked as a Senior Director-Global Supply Chain at Kadmon Pharmaceuticals LLC.
Yerace holds an undergraduate degree and an MBA from Waynesburg University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/03/2024 | 1 010 605 ( 2,80% ) | 300 150 $ | 31/03/2024 |
Postes actifs de Daniel Yerace
| Sociétés | Poste | Début |
|---|---|---|
| VININGS HOLDINGS INC. | Founder | - |
| COEPTIS THERAPEUTICS HOLDINGS, INC. | Chief Operating Officer | 28/10/2022 |
Coeptis Pharmaceuticals, Inc.
 Coeptis Pharmaceuticals, Inc. BiotechnologyHealth Technology Coeptis Pharmaceuticals, Inc. operates as a biopharmaceutical firm. It develops Consensi, a combination drug that is indicated for the treatment of osteoarthritis (OA) pain and hypertension. The company was founded by Dave Mehalick, Christine Sheehy, and Dan Yerace and is headquartered in Wexford, PA. | Founder | - |
Anciens postes connus de Daniel Yerace
| Sociétés | Poste | Fin |
|---|---|---|
Kadmon Pharmaceuticals LLC
 Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kadmon Pharmaceuticals LLC manufactures and distributes pharmaceutical products. The company is headquartered in Warrendale, PA. | Corporate Officer/Principal | - |
Formation de Daniel Yerace
| Waynesburg University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COEPTIS THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Coeptis Therapeutics, Inc.
 Coeptis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coeptis Therapeutics, Inc. is a pharmaceutical company focused on the development of therapeutics and technologies to disrupt conventional treatment paradigms. Its product portfolio includes CD38-GEAR-NK and a CD38-Diagnostic, which is focused on CD38-related cancers. The company was founded on February 15, 1996 and is headquartered in Wexford, PA. | Health Technology |
Kadmon Pharmaceuticals LLC
Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kadmon Pharmaceuticals LLC manufactures and distributes pharmaceutical products. The company is headquartered in Warrendale, PA. | Health Technology |
Coeptis Pharmaceuticals, Inc.
Coeptis Pharmaceuticals, Inc. BiotechnologyHealth Technology Coeptis Pharmaceuticals, Inc. operates as a biopharmaceutical firm. It develops Consensi, a combination drug that is indicated for the treatment of osteoarthritis (OA) pain and hypertension. The company was founded by Dave Mehalick, Christine Sheehy, and Dan Yerace and is headquartered in Wexford, PA. | Health Technology |
